Company news
TenNor Therapeutics Suzhou Ltd. news
Latest news releases, newest first.
Next Day Disclosure Returns
November 4, 2026
Next Day Disclosure Returns
November 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 2, 2026
Voluntary announcement development of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection as a priority indication
October 30, 2026
Next Day Disclosure Returns
October 27, 2026
Voluntary announcement h share repurchase plan
October 26, 2026
Articles of Association
October 23, 2026
Poll results of the 2026 second extraordinary general meeting held on Friday, October 23, 2026 and amendments to the articles of association
October 23, 2026
Voluntary announcement completion of enrollment of the first patient in the multi-center Phase IIb clinical trial of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection
October 22, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Form of proxy for 2026 second extraordinary general meeting to be held on October 23, 2026
October 2, 2026
Notice of 2026 second extraordinary general meeting
October 2, 2026
Circular of 2026 second extraordinary general meeting
October 2, 2026
2026 Interim report
September 24, 2026
Formulation of the 2026 h share award scheme; and (2) amendments to the articles of association
September 21, 2026
Poll results of the annual shareholders' meeting held on Monday, June 29, 2026
June 29, 2026